Subtype
Malignant Intestinal Neoplasm
CI-CAN-00001137Explore in graph →
1,666 active trials21 approved drugs383 evidence items
- NCIt
- C4572
Loading cancer entity…
Subtype
CI-CAN-00001137Explore in graph →
Clinical trials
7,771 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (772)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02980510 | Comparison FOLFIRINOX Panitumumab vs mFOLFOX6 Panitumumab in RAS/B-RAF Wild-type Metastatic Colorectal Cancer Patients(PANIRINOX) | completed | Phase 2 | 219 | UNICANCEROTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT05513742 | A Study of CTX-009 in Adult Patients With Metastatic Colorectal Cancer(COMPANION-003) | completed | Phase 2 | 49 | Compass TherapeuticsINDUSTRY | 1 | Sep 25, 2026 |
| clinicaltrials |
| NCT00989469 | Sorafenib With Irinotecan in Metastatic Colorectal Cancer (mCRC) and K-RAS Mutation(NEXIRI) | completed | Phase 1 / Phase 2 | 64 | Institut du Cancer de Montpellier - Val d'AurelleOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT04708470 | A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers | completed | Phase 1 / Phase 2 | 55 | National Cancer Institute (NCI)NIH | 1 | Sep 22, 2026 | clinicaltrials |
| NCT05004441 | Fruquintinib Combined With mFOLFOX6/FOLFIRI in First-line Treatment for Metastatic Colorectal Cancer | completed | Phase 2 | 43 | Zhou FuxiangOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT02587247 | ImmunoTEP With 68-Ga in Metastatic Colo Rectal Cancer(iTEP Colon) | completed | Phase 2 | 11 | Nantes University HospitalOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT05864144 | A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 98 | Sensei Biotherapeutics, Inc.INDUSTRY | 1 | Sep 2, 2026 | clinicaltrials |
| NCT03366155 | Hepatic Artery Infusion Pump Chemotherapy With Floxuridine and Dexamethasone in Combination With Systemic Chemotherapy for Patients With Colorectal Cancer Metastatic to the Liver | completed | Phase 2 | 24 | National Cancer Institute (NCI)NIH | 1 | Aug 28, 2026 | clinicaltrials |
| NCT04787341 | PAnitumumab REchallenge Followed by REgorafenib Versus the Reverse Sequence(PARERE) | completed | Phase 2 | 213 | Gruppo Oncologico del Nord-OvestOTHER | 1 | Aug 28, 2026 | clinicaltrials |
| NCT04902872 | Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors | completed | Phase 1 / Phase 2 | 69 | Cybrexa TherapeuticsINDUSTRY | 1 | Aug 20, 2026 | clinicaltrials |
| NCT04432597 | HPV Vaccine PRGN-2009 Alone or in Combination With Anti-PDL1/TGF-Beta Trap (M7824) in Subjects With HPV Associated Cancers | completed | Phase 1 / Phase 2 | 39 | National Cancer Institute (NCI)NIH | 1 | Aug 18, 2026 | clinicaltrials |
| NCT01394939 | Recombinant Vaccinia Virus Administered Intravenously in Patients With Metastatic, Refractory Colorectal Carcinoma | completed | Phase 1 / Phase 2 | 52 | Jennerex BiotherapeuticsINDUSTRY | 3 | Aug 5, 2026 | clinicaltrials |
| NCT06714292 | Fluorescent Approach for Refined Endoscopic Marking With Clip Localization and Identification Procedure(FLARECLIP) | completed | Phase 2 | 110 | Seoul National University HospitalOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT06908031 | SCRT+mFOLFOX6+PD-1 Antibody and Targeted Therapy for High-Risk pMMR/MSS Rectal Cancer(CRIT) | completed | Phase 2 | 49 | Sixth Affiliated Hospital, Sun Yat-sen UniversityOTHER | 1 | Aug 4, 2026 | clinicaltrials |
| NCT02821559 | Biweekly Versus Triweekly Raltitrexed With Oxaliplatin (With or Without Bevacizumab) in First-line Metastatic Colorectal Cancer(EROS) | completed | Phase 2 | 37 | Centre Hospitalier Universitaire de BesanconOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT05538195 | Safety and Efficacy of CEA-targeted CAR-T for CEA-positive Advanced Malignant Solid Tumors | completed | Phase 1 / Phase 2 | 17 | Chongqing Precision Biotech Co., LtdINDUSTRY | 1 | Jul 10, 2026 | clinicaltrials |
| NCT04895137 | mFOLFOX6+Bevacizumab+PD-1 Monoclonal Antibody in Local Advanced MSS CRC(BASKETⅡ) | completed | Phase 2 | 42 | Sixth Affiliated Hospital, Sun Yat-sen UniversityOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT04287868 | Combination Immunotherapy in Subjects With Advanced HPV Associated Malignancies | completed | Phase 1 / Phase 2 | 51 | National Cancer Institute (NCI)NIH | 1 | Jun 30, 2026 | clinicaltrials |
| NCT05185947 | Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis | completed | Phase 2 | 21 | National Cancer Institute (NCI)NIH | 1 | Jun 25, 2026 | clinicaltrials |
| NCT06884670 | Assessment of Efficacy and Safety of PD-1 Monoclonal Antibody Combined With IL-2 and CapeOX in Neoadjuvant Therapy for Locally Advanced Rectal Cancer Prior to Surgery: A Prospective, Multi-center, Randomized Controlled Study | completed | Phase 2 | 130 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT04457284 | Temozolomide, Cisplatin, and Nivolumab in People With Colorectal Cancer | completed | Phase 2 | 18 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT05546476 | Study of the Efficacy and Safety of Ponsegromab in Patients With Cancer, Cachexia and Elevated GDF-15(PROACC-1) | completed | Phase 2 | 187 | PfizerINDUSTRY | 11 | Jun 3, 2026 | clinicaltrials |
| NCT00159484 | Phase I/II Study of Celebrex and EPO906 in Patients With Metastatic Colorectal Cancer | completed | Phase 1 / Phase 2 | 75 | University of Southern CaliforniaOTHER | 1 | May 28, 2026 | clinicaltrials |
| NCT02350530 | FOLFOXIRI With or Without Bevacizumab as First-line Treatment for Unresectable Liver-only Metastatic Colorectal Cancer Patients With RAS Mutation-type(FORBES) | completed | Phase 2 | 138 | Sun Yat-sen UniversityOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT00959647 | A Study of Vismodegib (GDC-0449) in Patients Treated With Vismodegib in a Previous Genentech-sponsored Phase I or II Cancer Study | completed | Phase 2 | 19 | Genentech, Inc.INDUSTRY | 1 | May 8, 2026 | clinicaltrials |
| NCT04864067 | No Operation After Short Course Radiotherapy Followed By Consolidation Chemotherapy In Locally Advanced Rectal Cancer(NOAHS-ARC) | completed | Phase 2 | 39 | Servicio de Salud Metropolitano Sur OrienteOTHER_GOV | 1 | May 8, 2026 | clinicaltrials |
| NCT04130854 | INNATE: Immunotherapy During Neoadjuvant Therapy for Rectal Cancer | completed | Phase 2 | 58 | University of Texas Southwestern Medical CenterOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT03797326 | Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005) | completed | Phase 2 | 611 | Merck Sharp & Dohme LLCINDUSTRY | 17 | May 4, 2026 | clinicaltrials |
| NCT05004350 | A Study Evaluating the Combination of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or Infusional 5-fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab in Chinese Patients With BRAF V600E Mutant Metastatic Colorectal Cancer.(NAUTICALCRC) | completed | Phase 2 | 107 | Pierre Fabre MedicamentINDUSTRY | 1 | Apr 30, 2026 | clinicaltrials |
| NCT06428487 | Neoadjuvant Prolgolimab Monotherapy in Locally Advanced MMR-deficient Colorectal Cancer | completed | Phase 2 | 30 | Blokhin's Russian Cancer Research CenterOTHER | 1 | Apr 27, 2026 | clinicaltrials |
| NCT03981146 | A Phase II Trial Assessing Nivolumab in Class II Expressing Microsatellite Stable Colorectal Cancer(ANICCA) | completed | Phase 2 | 35 | University of BirminghamOTHER | 1 | Apr 22, 2026 | clinicaltrials |
| NCT02437851 | Surgery in Treating Patients With Early Stage Anal Canal or Perianal Cancer and HIV Infection | completed | Phase 2 | 16 | AIDS Malignancy ConsortiumNETWORK | 1 | Apr 20, 2026 | clinicaltrials |
| NCT04355156 | Axitinib Monotherapy With Early Dynamic Contrast Enhanced Ultrasound Monitoring in Chemorefractory Third Line Metastatic Colorectal Cancer(AXMUS-C) | completed | Phase 2 | 52 | Imperial College LondonOTHER | 1 | Apr 16, 2026 | clinicaltrials |
| NCT03259035 | NEO: Neoadjuvant Chemotherapy, Excision and Observation for Early Rectal Cancer | completed | Phase 2 | 58 | Canadian Cancer Trials GroupNETWORK | 2 | Apr 9, 2026 | clinicaltrials |
| NCT05515796 | Multi-omics Sequencing in Neoadjuvant Immunotherapy of Gastrointestinal Tumors | completed | Phase 2 | 189 | Daping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT02437656 | Combination of Metformin to Neoadjuvant Radiochemotherapy in the Treatment of Locally Advanced Rectal Cancer.(METCAP) | completed | Phase 2 | 60 | Centre Oscar LambretOTHER | 1 | Mar 31, 2026 | clinicaltrials |
| NCT05039177 | A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies(HERKULES-3) | completed | Phase 1 / Phase 2 | 101 | Erasca, Inc.INDUSTRY | 1 | Mar 25, 2026 | clinicaltrials |
| NCT03223779 | Study of TAS-102 Plus Radiation Therapy for the Treatment of the Liver in Patients With Hepatic Metastases From Colorectal Cancer | completed | Phase 1 / Phase 2 | 52 | Massachusetts General HospitalOTHER | 1 | Mar 12, 2026 | clinicaltrials |
| NCT02213913 | Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas | completed | Phase 1 / Phase 2 | 55 | University of ChicagoOTHER | 1 | Mar 11, 2026 | clinicaltrials |
| NCT03446157 | Palbociclib and Cetuximab in Metastatic Colorectal Cancer | completed | Phase 2 | 24 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT04705818 | Combining Epigenetic And Immune Therapy to Beat Cancer.(CAIRE) | completed | Phase 2 | 164 | Institut BergoniéOTHER | 1 | Mar 6, 2026 | clinicaltrials |
| NCT06608537 | A Clinical Study Based on FAPI-PET/CT Technology to Predict Pathological Complete Response After Neoadjuvant Chemoradiotherapy for MSS Rectal Cancer | completed | Phase 2 | 52 | Sun Yat-sen UniversityOTHER | 1 | Mar 4, 2026 | clinicaltrials |
| NCT03828799 | Safety, Tolerability and Efficacy of Regorafenib in Combination With FOLFIRINOX in Patients With Colorectal Cancer(FOLFIRINOX-R) | completed | Phase 1 / Phase 2 | 13 | Institut du Cancer de Montpellier - Val d'AurelleOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT04426669 | A Study of Metastatic Gastrointestinal Cancers Treated With Tumor Infiltrating Lymphocytes in Which the Gene Encoding the Intracellular Immune Checkpoint CISH Is Inhibited Using CRISPR Genetic Engineering | completed | Phase 1 / Phase 2 | 23 | Intima Bioscience, Inc.INDUSTRY | 1 | Feb 23, 2026 | clinicaltrials |
| NCT05116085 | Efficacy and Safety of Tislelizumab (BGB-A317) as Neo-Adjuvant Treatment in Participants With Colorectal Cancer | completed | Phase 2 | 33 | BeiGeneINDUSTRY | 1 | Feb 13, 2026 | clinicaltrials |
| NCT03365882 | S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery | completed | Phase 2 | 240 | SWOG Cancer Research NetworkNETWORK | 2 | Feb 10, 2026 | clinicaltrials |
| NCT04109924 | TAS-102, Irinotecan, and Bevacizumab for the Treatment of Pre-treated Metastatic or Unresectable Colorectal Cancer, the TABAsCO Study | completed | Phase 2 | 42 | Roswell Park Cancer InstituteOTHER | 1 | Feb 10, 2026 | clinicaltrials |
| NCT03693807 | A Study of the Use of the Medtronic Pump and Codman Catheter to Give Chemotherapy to Patients With Colorectal Carcinoma or Cholangiocarcinoma | completed | Phase 2 | 35 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 6, 2026 | clinicaltrials |
| NCT00208260 | Intensified Chemotherapy in CRC After Resection of Liver Metastases | completed | Phase 2 / Phase 3 | 124 | Institut du Cancer de Montpellier - Val d'AurelleOTHER | 1 | Feb 5, 2026 | clinicaltrials |
Data updated 7 hours agoSource updated Sep 29, 2026source: clinicaltrials